Anthony J Lembo

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Irritable bowel syndrome: toward an understanding of severity
    Anthony Lembo
    Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Clin Gastroenterol Hepatol 3:717-25. 2005
  2. ncbi Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder
    Anthony Lembo
    Department of Gastroenterology, Beth Israel Deaconess Hospital, Boston, Massachusetts 02215, USA
    Drugs 63:1895-905. 2003
  3. ncbi A 54-year-old woman with constipation-predominant irritable bowel syndrome
    Anthony J Lembo
    Harvard Medical School, Boston, Mass, USA
    JAMA 295:925-33. 2006
  4. pmc The Zelnorm epidemiologic study (ZEST): a cohort study evaluating incidence of abdominal and pelvic surgery related to tegaserod treatment
    John D Seeger
    Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    BMC Gastroenterol 12:171. 2012
  5. pmc A treatment trial of acupuncture in IBS patients
    Anthony J Lembo
    The Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Rabb Rose 1, Boston, MA 02215, USA
    Am J Gastroenterol 104:1489-97. 2009
  6. ncbi Irritable bowel syndrome medications side effects survey
    Anthony Lembo
    Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Clin Gastroenterol 38:776-81. 2004
  7. doi Clinical trial: renzapride treatment of women with irritable bowel syndrome and constipation - a double-blind, randomized, placebo-controlled, study
    A J Lembo
    Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center BIDMC, Harvard Medical School, Boston, MA 02215, USA
    Aliment Pharmacol Ther 31:979-90. 2010
  8. pmc Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation
    Anthony J Lembo
    Division of Gastroenterology, Harvard Medical School, 330 Brookline Ave, DA 501, Boston, MA, USA
    Dig Dis Sci 56:2639-45. 2011
  9. ncbi Chronic constipation
    Anthony Lembo
    Gastroenterology Division, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    N Engl J Med 349:1360-8. 2003
  10. ncbi Current gut-directed therapies for irritable bowel syndrome
    Howard Y Chang
    Beth Israel Deaconess Medical Center Harvard University Medical School, 330 Brookline Avenue, Dana 501, Boston, MA 02215, USA
    Curr Treat Options Gastroenterol 9:314-23. 2006

Collaborators

Detail Information

Publications37

  1. ncbi Irritable bowel syndrome: toward an understanding of severity
    Anthony Lembo
    Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Clin Gastroenterol Hepatol 3:717-25. 2005
    ..However, studies have not been adequately designed to determine the relative values of these factors in IBS severity...
  2. ncbi Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder
    Anthony Lembo
    Department of Gastroenterology, Beth Israel Deaconess Hospital, Boston, Massachusetts 02215, USA
    Drugs 63:1895-905. 2003
    ..Prescribing restrictions and the risk-management programme implemented as required by the US FDA is reviewed along with a summary of the studies to be performed after reintroduction of alosetron to monitor safety...
  3. ncbi A 54-year-old woman with constipation-predominant irritable bowel syndrome
    Anthony J Lembo
    Harvard Medical School, Boston, Mass, USA
    JAMA 295:925-33. 2006
  4. pmc The Zelnorm epidemiologic study (ZEST): a cohort study evaluating incidence of abdominal and pelvic surgery related to tegaserod treatment
    John D Seeger
    Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    BMC Gastroenterol 12:171. 2012
    ..We sought to quantify the association between tegaserod use and the occurrence of abdominal or pelvic surgery, including cholecystectomy...
  5. pmc A treatment trial of acupuncture in IBS patients
    Anthony J Lembo
    The Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Rabb Rose 1, Boston, MA 02215, USA
    Am J Gastroenterol 104:1489-97. 2009
    ..This study aimed to compare the effects of true and sham acupuncture in relieving symptoms of irritable bowel syndrome (IBS)...
  6. ncbi Irritable bowel syndrome medications side effects survey
    Anthony Lembo
    Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Clin Gastroenterol 38:776-81. 2004
    ..This study was conducted to determine the frequency and severity of side effects (SEs) experienced during treatment with standard medications used to treat patients with irritable bowel syndrome (IBS) with constipation (IBS-C)...
  7. doi Clinical trial: renzapride treatment of women with irritable bowel syndrome and constipation - a double-blind, randomized, placebo-controlled, study
    A J Lembo
    Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center BIDMC, Harvard Medical School, Boston, MA 02215, USA
    Aliment Pharmacol Ther 31:979-90. 2010
    ..Renzapride, a 5-hydroxytryptamine type-4 (5-HT(4)) receptor agonist and 5-HT(3) receptor antagonist, has been proposed as a new treatment of irritable bowel syndrome with constipation (IBS-C)...
  8. pmc Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation
    Anthony J Lembo
    Division of Gastroenterology, Harvard Medical School, 330 Brookline Ave, DA 501, Boston, MA, USA
    Dig Dis Sci 56:2639-45. 2011
    ..Lubiprostone helps relieve constipation in short-term 4-week studies. There are limited data on long-term pharmacological treatment with lubiprostone for chronic idiopathic constipation...
  9. ncbi Chronic constipation
    Anthony Lembo
    Gastroenterology Division, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    N Engl J Med 349:1360-8. 2003
  10. ncbi Current gut-directed therapies for irritable bowel syndrome
    Howard Y Chang
    Beth Israel Deaconess Medical Center Harvard University Medical School, 330 Brookline Avenue, Dana 501, Boston, MA 02215, USA
    Curr Treat Options Gastroenterol 9:314-23. 2006
    ..However, alosetron is available under a restricted license because of concerns for ischemic colitis and severe constipation necessitating colectomy. Clonidine may be helpful in alleviating global symptoms for D-IBS patients...
  11. doi Efficacy of linaclotide for patients with chronic constipation
    Anthony J Lembo
    Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Gastroenterology 138:886-95.e1. 2010
    ..We assessed the safety and efficacy of a range of linaclotide doses in patients with chronic constipation...
  12. ncbi Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety
    William D Chey
    Division of Gastroenterology, Department of Medicine, University of Michigan Health System, Ann Arbor, Michigan, USA
    Am J Gastroenterol 107:1702-12. 2012
    ..The objective of this trial was to determine the effi cacy and safety of linaclotide treatment in patients with irritable bowel syndrome with constipation (IBS-C) over 26 weeks...
  13. doi Two randomized trials of linaclotide for chronic constipation
    Anthony J Lembo
    Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA, USA
    N Engl J Med 365:527-36. 2011
    ..Linaclotide is a minimally absorbed peptide agonist of the guanylate cyclase C receptor. In two trials, we aimed to determine the efficacy and safety of linaclotide in patients with chronic constipation...
  14. doi Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation
    Jeffrey M Johnston
    Ironwood Pharmaceuticals, Inc, Cambridge, Massachusetts, USA
    Gastroenterology 139:1877-1886.e2. 2010
    ..We assessed the efficacy and safety of linaclotide at a daily dose range of 75-600 μg in IBS-C...
  15. pmc Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome
    Ted J Kaptchuk
    Osher Research Center, Harvard Medical School, 401 Park Drive, Boston, MA 02215, USA
    BMJ 336:999-1003. 2008
    ..To assess the relative magnitude of these components...
  16. pmc Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome
    Kathryn T Hall
    Division of General Medicine and Primary Care, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 7:e48135. 2012
    ..These data support our hypothesis that the COMT val158met polymorphism is a potential biomarker of placebo response...
  17. pmc "Maybe I made up the whole thing": placebos and patients' experiences in a randomized controlled trial
    Ted J Kaptchuk
    Osher Research Center, Harvard Medical School, 401 Park Drive, Boston, MA 02215, USA
    Cult Med Psychiatry 33:382-411. 2009
    ..g. expectancy, hope, conditioning, anxiety reduction, report bias, symbolic work, narrative and embodiment--provides an inadequate model to explain its salubrious benefits...
  18. pmc Adequate relief in a treatment trial with IBS patients: a prospective assessment
    Maria C F Passos
    Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Am J Gastroenterol 104:912-9. 2009
    ....
  19. pmc Placebos without deception: a randomized controlled trial in irritable bowel syndrome
    Ted J Kaptchuk
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 5:e15591. 2010
    ..We tested whether open-label placebo (non-deceptive and non-concealed administration) is superior to a no-treatment control with matched patient-provider interactions in the treatment of irritable bowel syndrome (IBS)...
  20. pmc Effectiveness of recruitment in clinical trials: an analysis of methods used in a trial for irritable bowel syndrome patients
    Siu Ping Chin Feman
    Osher Institute, Harvard Medical School, Boston, MA 02215, United States
    Contemp Clin Trials 29:241-51. 2008
    ..The iterative use of the efficacy index during a recruitment campaign may be helpful to calibrate and focus on the most effective recruitment methods...
  21. ncbi Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials
    Anthony J Lembo
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Clin Gastroenterol Hepatol 2:675-82. 2004
    ..The aim of this study was to assess the effect of alosetron on bowel urgency and irritable bowel syndrome (IBS) global improvement in diarrhea-predominant IBS (D-IBS)...
  22. doi Pilot study on the effect of linaclotide in patients with chronic constipation
    Jeffrey M Johnston
    Ironwood Pharmaceuticals, Inc, 320 Bent Street, Cambridge, MA, USA
    Am J Gastroenterol 104:125-32. 2009
    ..In Phase 1 studies in healthy human volunteers, linaclotide was well-tolerated, increased bowel movement frequency, and loosened stool consistency...
  23. ncbi Investigating placebo effects in irritable bowel syndrome: a novel research design
    Lisa A Conboy
    Osher Institute, Division for Research and Education in Complementary and Integrative Therapies, Harvard Medical School, 401 Park Drive, Suite 22A, Boston, MA 02115, USA
    Contemp Clin Trials 27:123-34. 2006
    ..quot; The trial also uses an innovative combination of quantitative and qualitative methods...
  24. pmc Patient and practitioner influences on the placebo effect in irritable bowel syndrome
    John M Kelley
    Psychology Department, Endicott College, 376 Hale Street, Beverly, MA 01915, USA
    Psychosom Med 71:789-97. 2009
    ..To determine whether placebo responses can be explained by characteristics of the patient, the practitioner, or their interpersonal interaction...
  25. pmc Which patients improve: characteristics increasing sensitivity to a supportive patient-practitioner relationship
    Lisa Ann Conboy
    Harvard Medical School, Osher Research Center, Boston, MA United States
    Soc Sci Med 70:479-84. 2010
    ..These results converge with the results of the parent trial, implicating the importance of the social world in healing...
  26. ncbi Peripheral opioids for functional GI disease: a reappraisal
    Anthony Lembo
    Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Dig Dis 24:91-8. 2006
    ..Further studies are on hold presumably due to lack of efficacy in subsequent studies. However, clinical studies are underway for newer kappa opioid agonists such as asimadoline and ADL 10-0101...
  27. ncbi Visceral hypersensitivity in noncardiac chest pain
    Anthony J Lembo
    Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Hospital, Dana 501, 330 Brookline Avenue, Boston, MA 02215, USA
    Gastroenterol Clin North Am 33:55-60. 2004
    ..The processing of visceral information and possibly the development of central sensitization may be important in NCCP, although the pathophysiology of NCCPremains poorly understood...
  28. doi Psychiatric disorder, irritable bowel syndrome, and extra-intestinal symptoms in a population-based sample of twins
    Anthony J Lembo
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Am J Gastroenterol 104:686-94. 2009
    ....
  29. ncbi Endoscopic full-thickness plication for the treatment of GERD: 12-month follow-up for the North American open-label trial
    Douglas Pleskow
    Division of Gastroenterology, Department of Medicne, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Gastrointest Endosc 61:643-9. 2005
    ..The aim of this study was to assess the intermediate-term (12-month) safety and efficacy of endoscopic full-thickness plication in patients with symptomatic GERD...
  30. doi Spasm, nutcracker, and IEM: real or manometry findings?
    Thomas Konturek
    Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Clin Gastroenterol 42:647-51. 2008
    ..Likewise, as no subjects had >20% simultaneous contractions (though a considerable number, 4%, had 10% simultaneous contractions), esophageal spasm was defined at the >20% mark...
  31. ncbi Endoscopic full-thickness plication for the treatment of GERD: a multicenter trial
    Douglas Pleskow
    Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Gastrointest Endosc 59:163-71. 2004
    ..This study assessed the safety and efficacy of endoscopic full-thickness plication in the treatment of patients with symptoms caused by GERD...
  32. doi Management of Crohn's disease in adults
    Gary R Lichtenstein
    Department of Medicine, Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Am J Gastroenterol 104:465-83; quiz 464, 484. 2009
    ..The final recommendations are based on the data available at the time of the production of the document and may be updated with pertinent scientific developments at a later time...
  33. ncbi Review of tegaserod in the treatment of irritable bowel syndrome
    Sonal Patel
    Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Expert Opin Pharmacother 5:2369-79. 2004
    ..Tegaserod was well-tolerated. The most common adverse reaction in clinical trials was diarrhoea, which was usually temporary and mild, although severe diarrhoea requiring hospitalisation has been rarely (< 1%) reported...
  34. ncbi A novel endoscopic full-thickness plicator for the treatment of GERD: A pilot study
    Ram Chuttani
    Harvard Medical School, Boston, Massachusetts, USA
    Gastrointest Endosc 58:770-6. 2003
    ..The aim of this study was to assess the safety and feasibility of endoscopic full-thickness plication for the treatment of patients with GERD symptoms...
  35. doi Delayed radionucleotide gastric emptying studies predict morbidity in diabetics with symptoms of gastroparesis
    Brian Hyett
    Division of Gastroenterology, Brigham and Women s Hospital, Boston, Massachusetts 02215, USA
    Gastroenterology 137:445-52. 2009
    ..The aim of this study was to evaluate the prognostic value of gastric emptying studies on the morbidity associated with diabetic gastroparesis...
  36. ncbi Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial
    John F Johanson
    University of Illinois College of Medicine, Rockford, IL, USA
    Clin Gastroenterol Hepatol 2:796-805. 2004
    ..Chronic constipation is a common gastrointestinal disorder. The aim of this study was to evaluate the efficacy, safety, and tolerability of tegaserod, a serotonin subtype 4 receptor partial agonist in patients with chronic constipation...
  37. ncbi Neurotrophin-3 improves functional constipation
    Henry P Parkman
    Temple University Hospital, Philadelphia, Pennsylvania 19140, USA
    Am J Gastroenterol 98:1338-47. 2003
    ..Our aim was to assess 1) the dose-related effects of NT-3 on bowel function, colon transit, and symptoms of chronic constipation, and 2) its safety...